NASDAQ:CRSPCrispr Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Crispr Therapeutics AG Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $39.38 -0.13 (-0.33 %) (As of 04/3/2020 04:00 PM ET) Add Compare Share Today's Range$39.10Now: $39.38▼$40.5550-Day Range$33.68MA: $47.20▼$58.1252-Week Range$32.30Now: $39.38▼$74.00Volume531,702 shsAverage Volume970,823 shsMarket Capitalization$2.40 billionP/E Ratio40.60Dividend YieldN/ABeta2.53 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. The company is also developing CTX110, a donor-derived gene-edited allogeneic CAR-T therapy targeting cluster of differentiation 19 positive malignancies. In addition, it is developing allogeneic CAR-T programs targeting B-Cell maturation antigen and CD70; CTX120, a CAR-T cell product candidate for the treatment of multiple myeloma; CTX130 for the treatment of solid tumors and hematologic malignancies; programs to treat Hurler Syndrome and severe combined immunodeficiency disease, as well as glycogen storage disease Ia; and programs targeting diseases, such as Duchenne muscular dystrophy and cystic fibrosis. It has a collaboration agreements with Vertex Pharmaceuticals, Incorporated and Vertex Pharmaceuticals (Europe) Limited to develop, manufacture, commercialize, sell, and use various therapeutics; and StrideBio LLC to develop adeno-associated viral capsids. The company also has research collaboration agreements with Neon Therapeutics for developing neoantigen-based therapeutic vaccines and T cell therapies; Massachusetts General Hospital Cancer Center to develop T cell therapies for cancer; ViaCyte, Inc. for designing, developing, and commercializing gene-edited allogeneic stem cell therapies for the treatment of diabetes; and ProBioGen AG to develop novel in vivo delivery modalities for CRISPR/Cas9. CRISPR Therapeutics AG is headquartered in Zug, Switzerland.Read More Beat the Market (BTM) Rank™ 4.4 Analyst's Opinion Consensus RatingCrispr Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 13 buy ratings, 2 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $74.42, Crispr Therapeutics has a potential upside of 89.0% from its current price of $39.38.Amount of Analyst CoverageCrispr Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.5 Community Rank Outperform VotesCrispr Therapeutics has received 331 “outperform” votes. (Add your “outperform” vote.)Underperform VotesCrispr Therapeutics has received 324 “underperform” votes. (Add your “underperform” vote.)Community SentimentCrispr Therapeutics has received 50.53% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Crispr Therapeutics and other stocks. Vote “Outperform” if you believe CRSP will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CRSP will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldCrispr Therapeutics does not currently pay a dividend.Dividend GrowthCrispr Therapeutics does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Crispr Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 21.40% of the stock of Crispr Therapeutics is held by insiders.Percentage Held by Institutions52.02% of the stock of Crispr Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Crispr Therapeutics are expected to grow by 11.23% in the coming year, from ($4.54) to ($5.05) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Crispr Therapeutics is 40.60, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 11.13.Price to Earnings Ratio vs. SectorThe P/E ratio of Crispr Therapeutics is 40.60, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 19.71.Price to Book Value per Share RatioCrispr Therapeutics has a P/B Ratio of 2.31. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 4.4Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.70 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CRSP Previous Symbol CUSIPN/A CIK1674416 Webhttp://www.crisprtx.com/ Phone41-41-561-3277Debt Debt-to-Equity RatioN/A Current Ratio17.29 Quick Ratio17.29Price-To-Earnings Trailing P/E Ratio40.60 Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$289.59 million Price / Sales8.27 Cash Flow$1.29 per share Price / Cash Flow30.46 Book Value$17.02 per share Price / Book2.31Profitability EPS (Most Recent Fiscal Year)$1.17 Net Income$66.86 million Net Margins23.09% Return on Equity11.74% Return on Assets9.62%Miscellaneous Employees188 Outstanding Shares60,850,000Market Cap$2.40 billion Next Earnings Date5/4/2020 (Estimated) OptionableOptionable Receive CRSP News and Ratings via Email Sign-up to receive the latest news and ratings for CRSP and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:CRSP Rates by TradingView Crispr Therapeutics (NASDAQ:CRSP) Frequently Asked Questions How has Crispr Therapeutics' stock been impacted by COVID-19 (Coronavirus)? Crispr Therapeutics' stock was trading at $43.28 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, CRSP stock has decreased by 9.0% and is now trading at $39.38. View which stocks have been mosted impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Crispr Therapeutics? 16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Crispr Therapeutics in the last year. There are currently 1 sell rating, 2 hold ratings and 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Crispr Therapeutics. When is Crispr Therapeutics' next earnings date? Crispr Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, May 4th 2020. View our earnings forecast for Crispr Therapeutics. How were Crispr Therapeutics' earnings last quarter? Crispr Therapeutics AG (NASDAQ:CRSP) posted its quarterly earnings data on Wednesday, February, 12th. The company reported $0.51 EPS for the quarter, beating the Zacks' consensus estimate of ($0.68) by $1.19. The business had revenue of $77 million for the quarter, compared to analysts' expectations of $39.08 million. Crispr Therapeutics had a net margin of 23.09% and a return on equity of 11.74%. The company's quarterly revenue was up 76900.0% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.92) EPS. View Crispr Therapeutics' earnings history. What price target have analysts set for CRSP? 16 Wall Street analysts have issued 1-year price targets for Crispr Therapeutics' shares. Their forecasts range from $31.00 to $104.00. On average, they expect Crispr Therapeutics' share price to reach $74.42 in the next year. This suggests a possible upside of 89.0% from the stock's current price. View analysts' price targets for Crispr Therapeutics. What are Wall Street analysts saying about Crispr Therapeutics stock? Here are some recent quotes from research analysts about Crispr Therapeutics stock: 1. According to Zacks Investment Research, "CRISPR Therapeutics AG is a gene-editing company. It focused on the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR Therapeutics AG is headquartered in Basel, Switzerland. " (3/24/2020) 2. Needham & Company LLC analysts commented, "Crispr reported 1Q19 financial results yesterday and we spoke w/ mgmt for an update. The company announced last night that regulatory agencies in both the U.S. and Canada have cleared initiation of a Phase 1/2 trial of CTX-110, an allogeneic CAR-T cell therapy in development for CD-19 cancers. Mgmt reiterated guidance for trial initiation in 2Q19. 1/2 trials of CTX-001 continue to enroll pts, although infusion of first pt in latter trial is not expected until mid-2019. Mgmt still aspires to present data from the CTX-001 program at the ASH mtg in Dec 2019, depending on trial progress. Reiterate BUY. Progression of CRISPR-based allogeneic CAR-T program into the clinic later in 2Q19 represents important milestone for the company." (5/1/2019) Has Crispr Therapeutics been receiving favorable news coverage? News articles about CRSP stock have trended very negative recently, according to InfoTrie Sentiment. The research group identifies negative and positive news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Crispr Therapeutics earned a news sentiment score of -3.3 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news aboutCrispr Therapeutics. Are investors shorting Crispr Therapeutics? Crispr Therapeutics saw a increase in short interest during the month of March. As of March 13th, there was short interest totaling 3,305,800 shares, an increase of 5.3% from the February 27th total of 3,140,000 shares. Based on an average daily volume of 906,900 shares, the days-to-cover ratio is presently 3.6 days. Currently, 12.5% of the company's shares are sold short. View Crispr Therapeutics' Current Options Chain. Who are some of Crispr Therapeutics' key competitors? Some companies that are related to Crispr Therapeutics include Qiagen (QGEN), Neurocrine Biosciences (NBIX), BIO-TECHNE (TECH), argenx (ARGX), Repligen (RGEN), Acceleron Pharma (XLRN), Spark Therapeutics (ONCE), China Biologic Products (CBPO), Ablynx (ABLYF), Iovance Biotherapeutics (IOVA), Adaptive Biotechnologies (ADPT), Momenta Pharmaceuticals (MNTA), Audentes Therapeutics (BOLD), Allogene Therapeutics (ALLO) and Halozyme Therapeutics (HALO). What other stocks do shareholders of Crispr Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Crispr Therapeutics investors own include Editas Medicine (EDIT), Micron Technology (MU), NVIDIA (NVDA), Intellia Therapeutics (NTLA), Alibaba Group (BABA), Advanced Micro Devices (AMD), Canopy Growth (CGC), Sangamo Therapeutics (SGMO), Intel (INTC) and Netflix (NFLX). Who are Crispr Therapeutics' key executives? Crispr Therapeutics' management team includes the following people: Dr. Rodger Novak, Founder, Chairman & Pres (Age 52)Dr. Samarth Kulkarni, CEO & Director (Age 40)Mr. Michael John Tomsicek, Chief Financial Officer (Age 53)Dr. Tony W. Ho, Head of R&D and Exec. VPDr. N. Anthony Coles Jr., Sr. Advisor (Age 59) When did Crispr Therapeutics IPO? (CRSP) raised $75 million in an IPO on Wednesday, October 19th 2016. The company issued 4,700,000 shares at $15.00-$17.00 per share. Citigroup, Piper Jaffray and Barclays acted as the underwriters for the IPO and Guggenheim Securities was co-manager. What is Crispr Therapeutics' stock symbol? Crispr Therapeutics trades on the NASDAQ under the ticker symbol "CRSP." How do I buy shares of Crispr Therapeutics? Shares of CRSP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Crispr Therapeutics' stock price today? One share of CRSP stock can currently be purchased for approximately $39.38. How big of a company is Crispr Therapeutics? Crispr Therapeutics has a market capitalization of $2.40 billion and generates $289.59 million in revenue each year. The company earns $66.86 million in net income (profit) each year or $1.17 on an earnings per share basis. Crispr Therapeutics employs 188 workers across the globe. View additional information about Crispr Therapeutics. What is Crispr Therapeutics' official website? The official website for Crispr Therapeutics is http://www.crisprtx.com/. How can I contact Crispr Therapeutics? Crispr Therapeutics' mailing address is BAARERSTRASSE 14, ZUG V8, CH-6300. The company can be reached via phone at 41-41-561-3277 or via email at [email protected] This page was last updated on 4/4/2020 by MarketBeat.com StaffFeatured Article: What are economic reports?
